Pharmaceuticals Related News

Amyris Enters Collaboration with Top 10 Pharmaceutical Company for Biosynthetic Drug Discovery

Amyris's Leading µPharm™ Platform Focused on Rapid Discovery of Novel Antibiotic Compound Target EMERYVILLE, Calif., Oct. 28, 2016 (GLOBE NEWSWIRE) -- Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, is pleased to announce it has entered into a research agreement with [...]

By | November 1st, 2016|BioPharma & Healthcare, News, Pharmaceuticals|

SynBioBeta Opens Memberships and Registration for San Francisco 2016

SynBioBeta is coming back to San Francisco this October 4th-6th at a new venue, the South San Francisco Conference Center, for the 5th Annual SynBioBeta SF 2016.  SynBioBeta SF 2016 is the prime conference for the synthetic biology industry, where [...]

Intrexon Responds to Short-Sellers’ Report

Holders of Intrexon Corporation stock are watching their portfolios carefully in wake of the anonymous publication last Thursday of a short-seller report that alleges the company’s technology is less cutting-edge than it claims and that its revenues are exaggerated. On [...]

Eli Lilly to Acquire ‘Smart Insulin’ Company Glycostasis, Inc

Eli Lilly and Company are acquiring Glycostasis, Inc., a startup aiming to create “smart insulin.” Seattle-based Glycostasis, founded by CEO Dr. John Mulligan, was incubated by Pacific Northwest Diabetes Research Institute (PNDRI), and later attracted Series A financing led by [...]

By | February 17th, 2016|BioPharma & Healthcare, News, Pharmaceuticals|

What’s Next for Synthetic Biology in Biopharmaceuticals?

In the world of biopharmaceuticals, synthetic biology has quickly started to revolutionize drug discovery and design by providing a better overall molecular understanding of disease. Throughout the industry, biologists and engineers have come together over the past several years to [...]

By | February 2nd, 2016|BioPharma & Healthcare, News, Pharmaceuticals|

Harvest Capital Strategies Raises $245M Fund for Companies Utilizing Tools of Intrexon

Harvest Capital Strategies announced Tuesday that it has raised $245 million to specifically finance companies utilizing the synthetic biology tools of Intrexon Corporation. This is big news for Intrexon, whose subsidiaries and their genetically modified products have been prominent in [...]